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Abstract 
Background: Ankyrin repeat and SOCS box protein 3 (ASB3) is a member of ASB family and contains ankyrin repeat 
sequence and SOCS box domain. Previous studies indicated that it mediates the ubiquitination and degradation of 
tumor necrosis factor receptor 2 and is likely involved in inflammatory responses. However, its effects on oncogenesis 
are unclear. This study aimed to investigate the effects of ASB3 on the growth and metastasis of colorectal cancer 
(CRC).
Methods: We used next‑generation sequencing or Sanger sequencing to detect ASB3 mutations in CRC specimens 
or cell lines, and used real‑time quantitative polymerase chain reaction, Western blotting, and immunohistochemical 
or immunofluorescence assay to determine gene expression. We evaluated cell proliferation by MTT and colony for‑
mation assays, tested cell cycle distribution by flow cytometry, and assessed cell migration and invasion by transwell 
and wound healing assays. We also performed nude mouse experiments to evaluate tumorigenicity and hepatic 
metastasis potential of tumor cells.
Results: We found that ASB3 gene was frequently mutated (5.3%) and down‑regulated (70.4%) in CRC cases. Knock‑
down of endogenous ASB3 expression promoted CRC cell proliferation, migration, and invasion in vitro and facilitated 
tumorigenicity and hepatic metastasis in vivo. Conversely, the ectopic overexpression of wild‑type ASB3, but not that 
of ASB3 mutants that occurred in clinical CRC tissues, inhibited tumor growth and metastasis. Further analysis showed 
that ASB3 inhibited CRC metastasis likely by retarding epithelial‑mesenchymal transition, which was characterized 
by the up‑regulation of β‑catenin and E‑cadherin and the down‑regulation of transcription factor 8, N‑cadherin, and 
vimentin.
Conclusion: ASB3 dysfunction resulted from gene mutations or down‑regulated expression frequently exists in CRC 
and likely plays a key role in the pathogenesis and progression of CRC.
Keywords: Ankyrin repeat and SOCS box protein 3 (ASB3), Colorectal cancer, Epithelial‑mesenchymal transition, Cell 
proliferation, Tumor metastasis
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Background
In developed countries, colorectal cancer (CRC) is the 
third most common cancer in men and the second most 
common cancer in women [1, 2]. Although the incidence 
and mortality of CRC are lower in developing countries, 
including China, than in developed countries, they are 
rapidly rising with increasing economic development [1, 
3]. Mounting evidences have confirmed that a series of 
gene mutations and epigenetic changes are involved in 
CRC tumorigenesis and progression [4–11]. Ubiquitina-
tion is a fundamental post-translational modification, 
and the ubiquitin–proteasome system plays an important 
role in regulating cell proliferation, apoptosis, angiogen-
esis, and motility. Additionally, abnormal regulations of 
the ubiquitin–proteasome system are known to promote 
colorectal carcinogenesis by regulating p53, Smad4, and 
components of the K-ras and Wnt/β-catenin pathways 
[12].
The ankyrin repeat and suppressor of cytokine signal-
ing (SOCS) box (ASB) family contains 18 proteins, which 
interact with Cul5-Rbx2 to form a functional E3 ubiquitin 
ligase [13]. ASB proteins likely function as the substrate-
recognition subunits of ElonginBC–Cullin–SOCS box 
(ECS)-type Cullin-Ring E3 ubiquitin ligase complexes 
that specifically transfer ubiquitin to cellular proteins for 
degradation by the proteasome [14]. ASB proteins, con-
taining a SOCS box, are involved in the negative regula-
tion of cytokine signaling [15]. Reportedly, ASB4 inhibits 
JNK activity and blocks insulin signal transduction by 
binding and inducing the ubiquitination and degrada-
tion of insulin receptor substrate 4 [16] and G-protein 
pathway suppressor 1 [17], as well as confers migration 
and invasion properties in hepatocellular carcinoma cells 
[18]. Furthermore, it was found that ASB9 expressed 
higher in CRC tissue than in corresponding normal tis-
sue; that knockdown of ASB9 promoted the invasion of 
CRC cells; and that patients who expressed low levels of 
ASB9 had a lower overall survival rate than those who 
expressed high levels of ASB9 [19].
Human ASB3 gene, another member of ASB gene fam-
ily, is located on chromosome 2p16.2. It has three tran-
script variants that encode two isoforms. Isoform A 
of ASB3 contains 518 amino acid residues [20], which 
form 11 coterminous ankyrin (ANK) repeats followed 
by a SOCS box domain in the C terminal of the peptide 
[NCBI (The National Center for Biotechnology Infor-
mation) Reference Sequence: NP_057199.1]. It has been 
reported that ASB3 mediates ubiquitination and degra-
dation of tumor necrosis factor receptor 2, which plays 
a crucial role in several inflammatory responses [21]. In 
this study, we detected the mutations and expression of 
ASB3 gene in CRC tissues and cells, and investigated the 
role of ASB3 in the pathogenesis of CRC.
Methods
Tissue samples
Paraffin-embedded and fresh frozen CRC specimens 
were collected from patients treated at Sun Yat-sen Uni-
versity Cancer Center, Guangzhou, China. All specimens 
contained matched cancer tissues (percentage of tumor 
cells ≥70%) and corresponding normal mucosal tissues 
(>5 cm laterally from the edge of the cancerous region). 
The study protocol was approved by the Institutional 
Review Board and the Human Ethics Committee of Sun 
Yat-sen University Cancer Center, and informed consent 
was obtained from each patient.
Cell lines and cell culture
Human normal colon epithelium cell line FHC; human CRC 
cell lines HT-29, COLO205, LoVo, HCT116, SW620, SW480, 
and DLD-1; and the human embryonic kidney cell line 293T 
were obtained from the American Type Culture Collection. 
Human CRC cell line THC8307 was kindly provided by 
Prof. Rui-Hua Xu at Sun Yat-sen University Cancer Center 
[22]. The FHC cell line was cultured in Dulbecco’s Modified 
Eagle Medium (DMEM)/nutrient mixture F-12 media con-
taining 100 ng/mL hydrocortisone, 10 ng/mL cholera toxin, 
5 μg/mL insulin, and 5 μg/mL transferrin supplemented with 
10% fetal bovine serum (FBS). COLO205 was cultured in 
RPMI-1640 medium supplemented with 10% FBS. All other 
cells were cultured in DMEM supplemented with 10% FBS. 
All materials for cell culture were from Invitrogen/Ther-
moFisher Scientific (Carlsbad, CA, USA).
ASB3 exonic sequence analysis
Genomic DNA was extracted from fresh frozen samples or 
cells using a Gentra Puregene Tissue Kit (Qiagen, Hilden, 
Germany). The exonic sequence was analyzed by next-gen-
eration sequencing at the Beijing Institute of Genomics, 
Chinese Academy of Sciences, Beijing, China. Sequencing 
files were deposited in the European Genome-phenome 
Archive under accession number EGAS00001001088. The 
exon sequence of the ASB3 gene was analyzed by Sanger 
sequencing at Invitrogen Trading (Shanghai) Co. Ltd 
(Shanghai, China).
Small interfering RNAs and transient transfection
ASB3 small interfering RNAs (siRNAs) and negative con-
trol siRNA (sequences are shown in Table  1) were syn-
thesized by Shanghai GenePharma Co. Ltd. (Shanghai, 
China). For transient transfection, THC8307 (2  ×  105/
well) or SW620 cells (4  ×  105/well) were seeded in 
6-well plates for 24 h and then transfected with siRNAs 
(100  pmol/well) using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s instructions. The cells 
were cultured for 24 h in standard media and then used 
for further analysis at the indicated time points.
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Retroviral expression vector construction, packaging, 
and stable cell line construction
To generate retroviral expression vectors, the frag-
ments of human wild type (WT) ASB3 and the artificial 
loss-of-function ASB3 mutant ΔSOCS [21] were ampli-
fied by polymerase chain reaction (PCR) from cDNA 
of THC8307 cells with specific primers (Table  2) and 
cloned into Xho I and Not I (or Cla I) sites of pLNCX2 
plasmid (Clontech, Mountain View, CA, USA). ASB3 
mutant-expressing vectors were generated using the 
GENEART site-directed mutagenesis system (Invitro-
gen) based on WT ASB3-expressing vector with spe-
cific primers (Table  2). All constructs were verified by 
DNA sequencing analysis. The retroviruses were then 
packaged and tittered following the manufacturer’s 
instructions.
To construct stable ASB3-overexpressing cells, 
HCT116 or DLD-1 cells that endogenously expresses 
the mutated ASB3 at a low level were infected with each 
retrovirus with 8  μg/mL of polybrene (Sigma-Aldrich, 
Milwaukee, WI, USA) and then were selected with G418 
(Calbiochem, La Jolla, CA, USA) for 2–3 weeks.
Real‑time quantitative PCR assay
Real-time quantitative PCR (qPCR) analysis was con-
ducted as described previously [23]. Briefly, total RNA 
was extracted with Trizol Reagent (Invitrogen), reversely 
transcribed into cDNA with M-MLV reverse transcriptase 
(Promega, Madison, WI, USA), and sequentially subjected 
to qPCR analysis with the SYBR Green PCR Kit (Invitro-
gen) using primers shown in Table 2. The threshold cycle 
(Ct) values were determined and normalized against that 
of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
internal control. The relative mRNA levels were shown as 
the value of 2−ΔCt against the control group [24].
Western blotting analysis
Western blotting was performed as described previously 
[24, 25]. Briefly, cell pellets were lysed in RIPA lysis buffer 
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) 
followed by centrifugation to remove insoluble materials. 
Protein were then separated by using sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis and transferred to 
polyvinylidene fluoride membrane. Blots were probed with 
specific primary antibody for ASB3 (1:250, Novus Biologi-
cals, Littleton, CO, USA); E-cadherin, N-cadherin, vimen-
tin, transcription factor 8 (TCF8), β-catenin, and zonula 
occludens-1 (ZO-1) (1:1000; Cell Signaling Technology, 
Inc., Beverly, MA, USA); and GAPDH (1:2000; Santa Cruz 
Biotechnology, Inc.), followed by reaction with horseradish 
peroxidase-conjugated secondary antibody. Signals were 
visualized using the enhanced chemiluminescent detection 
system (Amersham Biosciences, Piscataway, NJ, USA).
Immunohistochemical assay
Protein levels of ASB3 were detected by immunohis-
tochemical (IHC) assay with a peroxidase kit (DAKO, 
Carpinteria, CA, USA) as described previously [26, 
27]. Briefly, after routine deparaffinization, rehydra-
tion, and blocking with 0.3% H2O2 and antigen retrieval, 
the slides were incubated overnight at 4  °C with rabbit 
anti-ASB3 antibody (1:400, NBP1-88,812; Novus Bio-
logicals), followed by incubation with HRP-conjugated 
secondary antibody and visualized with the EnVision 
Detection Kit (DAKO). Then, the sections were coun-
terstained with hematoxylin. ASB3 staining intensity (I0, 
Table 1 The sequences of  small interfering RNAs (siRNAs) 
involved in this study
Target Name Direction Sequences



















For vector construction (italics indicates restriction enzyme recognition 
sequence)




For point mutation generation (capital letter indicates mutated nucleo‑
tide)
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negative; I1, weak; I2, moderate; and I3, strong)  (repre-
sentative images shown in Fig.  1a) and the percentage 
of corresponding positive area (P1-P3) were evaluated by 
two pathologists who were blinded to clinical parame-
ters. The ASB3 protein levels were presented as H score: 
H score = I1 × P1 + I2 × P2 + I3 × P3 [23, 28, 29].
Cell proliferation assay
Cell proliferation was analyzed using MTT and colony 
formation assays as described previously [23, 25, 30]. For 
the MTT assay, cells were seeded in 96-well plates with 
a density of 2000 cells/well and incubated for indicated 
times. Cells were stained with MTT, and then absorbance 
was determined at 490  nm. For the colony formation 
assay, cells were seeded in 6-well plates at 500 cells/well 
and maintained in standard media for 14 days. Colonies 
were fixed with 4% paraformaldehyde and stained with 
crystal violet, and the ones containing more than 50 cells 
were counted.
Cell cycle analysis
Cells were collected by centrifugation (1000  rpm  ×   
10  min) after trypsinization, washed with ice-cold PBS 
twice, and fixed in 70% ethanol at 4 °C overnight. Cell sus-
pensions were washed and re-suspended in PBS, treated 
with RNase A, and stained with propidium iodide. Finally, 
flow cytometry was performed to analyze cell cycle distri-
bution [31].
Wound healing assays
After serum deprivation for 12  h, confluent monolay-
ers were scratched using a 10-μL pipette tip and washed 
once with serum-free medium to create a cell-free gap. 
Then, cells were incubated in DMEM medium containing 
10% FBS. Wound healing in the same field was monitored 
and photographed under a microscope every 6 h from 0 
to 36 h post-scratch [32, 33]. Using the Image-J software, 
images were then analyzed and calculated [34] to deter-
mine the rate of cell migration.
Migration and invasion assays
Transwell assays were used to measure the migration or 
invasion ability of cells. In 200 μL of serum-free medium, 
1 × 105 cells were seeded into a Boyden chamber without 
or with Matrigel (8-μm pore; BD Falcon, San Jose, CA, 
USA) for migration or invasion assay, respectively; then 
the chambers were put in 24-well plates with 600 μL of 
medium containing 10% FBS. After 16–24  h of incuba-
tion, cells on the underside of the polycarbonate mem-
brane were fixed in ethanol and stained with crystal 
violet; the numbers of migratory or invasive cells were 
determined from seven independent microscopic fields 
(200×).
Immunofluorescence assays
Immunofluorescence assay was performed to detect the 
expression of epithelial-mesenchymal transition (EMT) 
markers. Cells cultured in glass-bottom cell culture 
dishes (NEST Biotechnology Co., Ltd., Wuxi, Jiangsu, 
China) were fixed with 4% paraformaldehyde, permea-
bilized with 0.5% Triton X-100, and blocked with 4% 
bovine serum albumin. Then, they were incubated with 
primary antibodies (Cell Signaling Technology, Inc.) for 
E-cadherin (1:100), vimentin (1:200), β-catenin (1:200), 
or N-cadherin (1:100) overnight at 4  °C, followed by 
incubation with Alexa fluor-594-conjugated or Alexa 
fluor-488-conjugated secondary antibody (Invitrogen). 
The samples were co-stained with DAPI and imaged by 
confocal laser scanning microscopy (Olympus FV1000; 
Olympus, Tokyo, Japan) [27].
In vivo tumorigenicity and hepatic metastasis assays
Female BABL/c nude mice (4–5  weeks old) were pur-
chased from the Experimental Animal Center of Guang-
dong Province, Guangzhou, China. All animal studies 
were performed following the United States National 
Institutes of Health (NIH) animal use guidelines and the 
current Chinese regulations and standards on the use of 
laboratory animals. All animal procedures were approved 
by the Sun Yat-sen University Institutional Animal Care 
and Use Committee.
For the tumorigenicity assay, the mice were injected 
subcutaneously with 1 × 106 HCT116 cells overexpress-
ing WT ASB3, ASB3 mutants [ΔSOCS, G135E, K339I, or 
G135E/K339I (a natural mutant containing G135E and 
K339I)], or vector-transfected control cells in 100 μL PBS 
(eight mice per group). Xenograft formation was moni-
tored, tumor size was measured every 4 days, and tumor 
volume (V) was calculated according to the following 
formula: V =  0.52 × width2 ×  length [31, 35, 36]. Four 
weeks after implantation, the mice were euthanized, and 
the tumors were removed, photographed, and weighed.
For the hepatic metastasis assay, mice were anesthe-
tized and subjected to laparotomy. One million HCT116 
cells overexpressing WT ASB3 or ASB3 mutants or con-
trol cells in 20 μL PBS were respectively injected into the 
distal tip of the spleen (8 mice per group). Six weeks after 
incubation, the mice were euthanized and the spleens 
and livers were removed for pathologic examination [26, 
27].
Statistical analysis
All in  vitro experiments were performed at least three 
times; all in  vivo experiments were performed twice. 
Statistical analysis was conducted using the SPSS ver-
sion 16.0 software (SPSS Inc., Chicago, IL, USA). Dif-
ferences were analyzed by one-way analysis of variance 
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(ANOVA) or exact χ2 test. Metering data are presented 
as mean ± standard deviation (SD). P values < 0.05 were 
considered statistically significant.
Results
ASB3 gene was frequently mutated in CRC tissues and cell 
lines
Using next-generation sequencing (for 50 cases) and 
Sanger sequencing assays (for 83 new cases and 3 
cases with ASB3 mutations found in next-generation 
sequencing assays), we analyzed the ASB3 gene muta-
tions in tumor tissues collected from 133 CRC patients 
treated at Sun Yat-sen University Cancer Center, and 
found that ASB3 gene had a high frequency of somatic 
mutations (5.3%, 7/133). We also performed Sanger 
sequencing to analyze ASB3 gene exons in the normal 
intestinal epithelial cell line FHC and in CRC cell lines 
HCT116, HT-29, SW480, SW620, DLD-1, THC8307, 
CoLo205, and LoVo. We found that the ASB3 gene 
mutated in HCT116, HT-29, and DLD-1 cells but not in 
other cells. The mutation types included missense, non-
sense, and splice site mutations; of these, only missense 
mutations K339I and G135E occurred in Chinese CRC 
patients (Table 3).
ASB3 was down‑regulated in most CRC tissues and cell 
lines
We detected the expression of ASB3 by using IHC, qPCR 
and Western blotting assays. IHC assay for 274 CRC sam-
ples showed that average ASB3 protein levels were signif-
icantly lower in tumor tissues than in paratumor mucosa 
(P  <  0.001) and that 70.4% (193/274) of CRC cases 
exhibited a down-regulated expression in tumor tissues 
(Fig.  1b, c). qPCR and Western blotting assays showed 
that ASB3 mRNA levels were significantly lower in CRC 
tissues than in paired normal colorectal mucous epithe-
liums (n = 48, P = 0.016; Fig. 1d) and that ASB3 protein 
levels were lower in 75.0% (9/12) of tumor tissues than 
in paired normal epithelial tissues (Fig. 1e). The examina-
tion of ASB3 expression in CRC cell lines revealed similar 
results: ASB3 expression was decreased at both mRNA 
and protein levels in CRC cells compared with FHC cells 
(Fig.  1f, g). These data suggest that ASB3 expression is 
down-regulated in CRC.
ASB3 inhibited the proliferation of CRC cells in vitro
Since the ASB3 gene is frequently mutated or down-regu-
lated in CRC, we assumed that dysfunction of ASB3 likely 
plays a role in the pathogenesis and progression of the 
disease. To confirm this hypothesis, first, we analyzed the 
effect of ASB3 on the proliferation of CRC cells in vitro. 
We performed ASB3 knockdown in THC8307 and SW620 
CRC cells that are with relatively high levels of WT ASB3 
(Table 3; Figs. 1f, g, 2a) and then analyzed cell prolifera-
tion by MTT and colony formation assays. We found that 
the knockdown of ASB3 significantly promoted CRC cell 
proliferation (Fig. 2b, c) and colony formation (Fig. 2d).
We performed colony formation assays in HCT116 
CRC cells with a mutated ASB3 gene which was 
expressed at a lower level (Fig.  1f, g; Table  3). We sta-
bly transfected ASB3 cDNA or its mutants G135E, 
K339I, or R362C that were detected in clinical CRC 
Table 3 ASB3 gene mutations in colorectal cancer tissues and cell lines
ASB3, ankyrin repeat and suppressor of cytokine signaling (SOCS) box protein 3
The nucleotides in bold indicate the one mutated
a CDS coding domain sequence; A, T, C, G, four types of nucleotides; R = A/G; Y = C/T; W = A/T; K = G/T
b amino acid codon
Mutation genotype Mutation type Exon Codon change Amino acid change Case ID/Cell line
Colorectal cancer tissues
 CDS 21C→Ga Nonsense Exon 2 TAC→TAGb Y7stop C56
 chr2:53810098 G→C Splice‑site Exon 3/Intron – – C53
 CDS 404G→R Missense Exon 4 GGA→GAA G135E S78, S64
 CDS 1084C→Y Missense Exon 8 CGC→TGC R362C S35
 CDS 1016A→W Missense Exon 8 AAA→ATA K339I S12, S61, S64
Colorectal cancer cell lines
 CDS 471A→T Missense Exon 5 GAA→GAT E157D HCT116
 CDS 471A→W Missense Exon 5 GAA→GAT E157D HT‑29
 CDS 24G→R Synonymous Exon 2 GCG→GCA Non DLD‑1
 CDS 25G→K Missense Exon 2 GAC→TAC D9Y DLD‑1 
 CDS 154T→Y Missense Exon 2 TAT→CAT Y52H DLD‑1 
 CDS 922G→R Missensee Exon 7 GCC→ACC A308T DLD‑1 
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Fig. 1 Ankyrin repeat and suppressor of cytokine signaling (SOCS) box protein 3 (ASB3) is generally down‑regulated in colorectal cancer (CRC) 
tissues and cell lines. ASB3 expression was detected by immunohistochemical (IHC), real‑time quantitative polymerase chain reaction (qPCR), 
and Western blotting assays in CRC tissues (a, b, c, d and e) and cell lines (f and g). a Representative images of IHC staining for ASB3 in CRC tissues. 
ASB3 protein expression levels were divided into 4 levels: I0, negative; I1, weak staining; I2, moderate staining; I3, strong staining. The scale bar repre‑
sents 50μm. b ASB3 protein levels (H score) determined by IHC assay in 274 pairs of CRC and corresponding normal mucosal tissues (***P < 0.001). 
c IHC H‑scores ordered from low to high respectively. d The relative mRNA levels of ASB3 in 48 pairs of CRC and corresponding normal mucosal tis‑
sues (normalized against that of glyceraldehyde‑3‑phosphate dehydrogenase [GAPDH] internal control; *P = 0.016). e ASB3 protein levels detected 
by Western blotting assay in 12 pairs of CRC tissues (T) and corresponding normal mucosal tissues (N). GAPDH was used as a loading control. f 
ASB3 mRNA levels detected by qPCR in normal intestinal epithelial cell line FHC and 8 CRC cell lines (***P < 0.001 compared with FHC cells). g ASB3 
protein levels detected by Western blotting assay in cell lines; GAPDH was used as a loading control
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tissues (Table 3) or ΔSOCS into HCT116 cells. The data 
showed that ectopic overexpression of WT ASB3 inhib-
ited HCT116 cell colony formation (Fig. 2e, f ). However, 
overexpressing ASB3 mutants, including G135E, K339I, 
R362C, or ΔSOCS, did not inhibit HCT116 cell colony 
formation. On the contrary, K339I seemingly promoted 
colony formation (Fig. 2f ). The inhibitory effects of these 
mutants (except R362C) on HCT116 cell colony forma-
tion were significantly different from that of WT ASB3 
(Fig. 2f ). This indicates that these mutants likely lose the 
inhibitory effect of WT ASB3 on CRC cell proliferation.
Next, we analyzed cell cycle distributions in THC8307 
cells after ASB3 knockdown and found that the down-
regulation of ASB3 expression promoted THC8307 cells 
from G1 into S phase of the cell cycle. In THC8307 cells 
transfected with ASB3 siRNAs, the percentage of cells 
at G1 phase was significantly lower, and the percentage 
of cells at S phase was higher than those in control cells 
Fig. 2 ASB3 inhibits the proliferation of CRC cells in vitro. ASB3 protein levels, cell proliferation, or cell cycle distributions were analyzed in CRC 
cells using Western blotting assay (a and e), MTT assay (b and c), colony formation assay (d and f), or flow cytometry (g) after ASB3 knockdown by 
transiently transfected with small interfering RNAs (siRNAs) or after ASB3 overexpression by stably transfected with ASB3 cDNA or its mutants. siNC, 
negative control siRNA; WT, wild type; G135E, K339I, R362C, and ΔSOCS are ASB3 mutants. Representative pictures are also included in d, f, and 
g. *P < 0.05 compared with those transfected with siNC or vector control; ♦P < 0.05 compared with that transfected with WT ASB3; ***P < 0.001 
compared with that transfected with siNC
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(P < 0.001, Fig. 2g). This indicates that ASB3 inhibits CRC 
cell proliferation as a tumor suppressor and that dysfunc-
tions of ASB3 resulting from mutations or down-reg-
ulation are among the possible events that lead to CRC 
pathogenesis or progression.
ASB3 inhibited the migration and invasion of CRC cells 
in vitro
After artificially regulating ASB3 expression in CRC cells 
as described above, we investigated the effects of ASB3 on 
cell migration and invasion in  vitro. We found that ASB3 
knockdown facilitated wound healing, transwell migration, 
and invasion in THC8307 and SW620 CRC cells (Fig. 3a–f), 
whereas the overexpression of WT ASB3 suppressed cell 
migration and invasion in HCT116 CRC cells (Fig.  3g–j). 
However, ASB3 mutants G135E, K339I, or G135E/K339I did 
not hinder but actually promoted HCT116 cell migration. 
Mutant ΔSOCS had no effect on cell migration, whereas 
mutant R362C acted similarly to WT ASB3 (Fig. 3g, h). The 
effects of ASB3 mutants G135E, K339I, G135E/K339I, and 
ΔSOCS (except R362C) on HCT116 cell migration were 
markedly different from that of WT ASB3 (Fig. 3h). Similar 
results were obtained from the invasion assay (Fig. 3i, j).
ASB3 inhibited the tumorigenicity and hepatic metastasis 
of CRC cells in nude mice
To further elucidate the effects of ASB3 on the oncogen-
esis and progression of CRC, HCT116 cells stably over-
expressing ASB3 cDNA or its mutants (1 × 106 cells each 
mouse) were subcutaneously or intrasplenically injected 
into nude mice, and the tumorigenicity and hepatic 
metastasis were investigated. We found that, in subcuta-
neous implant model, the tumor formation rates of sub-
cutaneous xenografts of HCT116 cells overexpressing 
WT ASB3, ASB3 mutants G135E, K339I, G135E/K339I, 
and ΔSOCS were 37.5% (3/8), 75.0% (6/8), 87.5% (7/8), 
87.5% (7/8), and 75.0% (6/8), respectively, whereas that of 
vector-transfected control cells was 75.0% (6/8) (Fig.  4a). 
The tumorigenicity of xenografts derived from HCT116 
cells overexpressing WT ASB3 was lower, the volume of 
the tumors was smaller, and the weight of the tumors was 
lighter than those of xenografts from cells overexpress-
ing ASB3 mutants or control cells (all P values  <  0.05, 
Fig. 4b, c). In intrasplenic injection models, we found that 
overexpressing WT ASB3 in HCT116 cells suppressed 
intrasplenic tumor formation and hepatic metastasis 
(Table  4; Fig.  4d, e, f ). However, overexpressing ASB3 
mutants G135E, K339I, and G135E/K339I in turn facili-
tated hepatic metastasis (P < 0.05), whereas loss-of-func-
tion mutant ΔSOCS had no effects on hepatic metastasis 
(Table 4; Fig. 4d, e, f ). These data indicate that overexpres-
sion of WT ASB3 may suppress the tumorigenicity and 
hepatic metastasis of HCT116 cells in nude mice, whereas 
ASB3 mutants G135E, K339I, and G135E/K339I lose the 
inhibitory functions.
ASB3 inhibited the EMT of CRC cells
Since ASB3 inhibited the metastasis of CRC cells in vitro 
and in  vivo, we investigated whether ASB3 regulates 
EMT or not by Western blotting and immunofluores-
cence assays. The results showed that ASB3 knockdown 
resulted in the down-regulation of β-catenin and epithe-
lial marker E-cadherin and the up-regulation of TCF8 
and mesenchymal markers N-cadherin and vimentin in 
THC8307 and SW620 CRC cells (Fig. 5a, b). Conversely, 
the ectopic overexpression of ASB3 led to the up-regu-
lation of β-catenin and E-cadherin and down-regulation 
of TCF8, N-cadherin, and vimentin (Fig. 5c, d). However, 
we found no obvious changes of these markers’ expres-
sion after overexpressing ASB3 mutants G135E, K339I, 
or G135E/K339I compared with the control (Fig. 5c, d).
Discussion
ASB proteins were initially considered negative regula-
tors of cytokine signaling because they contain SOCS box 
domain [15, 37]. However, mounting evidence has shown 
that ASB proteins are involved in many cellular processes 
and pathways. ASB11, an endoplasmic reticulum-asso-
ciated ubiquitin ligase, interacts with and promotes the 
ubiquitination of ribophorin 1, which is involved in the 
glycosylation of nascent proteins [38]. ASB9 interacts 
with and promotes the ubiquitination and degradation 
of creatine kinase, and inhibits cell growth by negatively 
regulating mitochondrial energy metabolism [14, 39, 
40]. ASB2α enhances adhesion of hematopoietic cells to 
fibronectin by degradating filamin A [41]. Furthermore, 
ASB2-involved ECS-type Cullin RING E3 ubiquitin ligase 
complex mediates mixed lineage leukemia (MLL) protein 
degradation during hematopoietic differentiation. One 
critical cause for MLL is likely that MLL fusion protein 
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Fig. 3 ASB3 inhibits the migration and invasion of CRC cells in vitro. The migration and invasion abilities of CRC cells were detected by wound 
healing and transwell assays after ASB3 knockdown by transiently transfected with siRNAs or overexpression by stably transfected with ASB3 cDNA 
or its mutants. siNC negative control siRNA; WT wild type; G135E, K339I, R362C, and ΔSOCS are ASB3 mutants. a and b Wound healing assay, c and 
d transwell migration assay, and e and f invasion assay in THC8307 and SW620 cells after ASB3 knockdown. g and h transwell migration and i and j 
invasion assays in HCT116 cells after ASB3 (WT or mutants) overexpression. **P < 0.01, ***P < 0.001 compared with siNC or vector control; ♦P < 0.01 
compared with that transfected with WT ASB3
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derived from chromosomal translocation is unable to be 
degraded due to the loss of the ASB2-binding site [42].
In the present study, we found that the ASB3 gene had 
a high frequency of somatic mutations: it was mutated 
in 5.26% (7/133) of CRC cases and in HCT116, HT-29, 
and DLD-1 CRC cell lines. However, we observed that 
there are no obvious mutation hotspots in the ASB3 
gene in CRC (we consider that G135E and K339I are 
mutations reoccurred only in low frequency in CRC 
cases). Expression analysis showed that ASB3 was fre-
quently down-regulated in CRC tissues and cell lines. 
Further investigations showed that the knockdown of 
ASB3 promoted cell proliferation, migration, and inva-
sion in cultured CRC cells, whereas the overexpression 
of WT ASB3 inhibited cell proliferation, migration, and 
invasion in vitro and reduced tumorigenicity and hepatic 
metastasis of CRC xenografts in  vivo. Furthermore, we 
found that overexpression of ASB3 inhibited EMT of 
CRC cells, characterized by up-regulating epithelial 
markers β-catenin and E-cadherin and down-regulating 
mesenchymal markers TCF8, N-cadherin, and vimentin 
[43, 44]. Conclusively, ASB3 exerts a tumor-suppressive 
role in the pathogenesis and progression of CRC. How-
ever, the molecular mechanisms of how ASB3 regu-
lates the proliferation, migration, and invasion remain 
unknown.
Like other ASB family members, ASB3 consists of an 
N-terminal ANK repeat domain (ARD) and a C-terminal 
SOCS box. Human ASB3 ARD contains 11 ANK repeats, 
called ANK1 to ANK11 (NCBI Reference Sequence: 
NP_057199.1), and is different from murine ASB3 that 
contains 12 ANK repeats [20, 21]. The ANK repeats are 
responsible for substrate recognition, whereas the SOCS 
box is responsible for assembling Elongin B/C, Cul5, 
and Rbx2 to form the E3 ubiquitin ligase complex [45]. 
Our current study demonstrated that not only ASB3 
ΔSOCS mutant but also G135E, K339I, and G135E/
K339I mutants that were detected in CRC cases lost the 
tumor-suppressive function of WT ASB3. Surprisingly, 
in some experiments, ASB3 mutants G135E, K339I, and 
G135E/K339I even displayed the opposite oncogenic 
effects. ASB3 mutant ΔSOCS loses its function result-
ing from the failure to recruit and compose E3 ubiquitin 
ligase complex. The ASB3 G135E mutation, encoded by 
exon 4, leads to an additional negative charge in ANK4 in 
physiological condition, whereas K339I, encoded by exon 
8, leads to a loss of positive charge in ANK10. Theoreti-
cally, these two mutations will affect the spatial structure 
of ARD of ASB3, which is verified by the altered three-
dimensional structure predicted by SWISS-MODEL 
(Fig.  6). Thus, we speculate that these ASB3 mutants 
affect substrate recognization, which makes ASB3 no 
longer recognize its original substrates, or even recognize 
novel substrates. The former case will result in a loss of 
the functions of WT ASB3, whereas the latter will bring 
in a novel function.
There are several limitations in our study. First, we did 
not clarify whether the ASB3 dysfunction resulted from 
gene mutations or down-regulated expression affects the 
Table 4 The number and  percentages of  intrasplenic 
and  hepatic tumor formation after  intrasplenic injection 
of HCT116 stable cell lines (1×106 cells each) for 8 weeks
* P < 0.05 compared with other groups (Students’ t test)
a  The data are presented as the number of mice with tumors followed by 
percentage in parentheses
Modified HCT116 stable 
cell line
Number of mice Tumor formationa
Intrasplenic Liver
Vectro 8 6 (75.0) 6 (75.0)
ΔSOCS 8 6 (75.0) 6 (75.0)
WT ASB3 8 4 (50.0) 2 (25.0)*
G135E 8 7 (87.5) 8 (100)
K339I 8 7 (87.5) 8 (100)
G135E/K339I 8 8 (100) 8 (100)
(See figure on previous page.) 
Fig. 4 ASB3 inhibits the tumorigenicity and hepatic metastasis of CRC cells in vivo. HCT116 cells stably transfected with ASB3 cDNA or its mutants 
(1 × 106 cells each) were subcutaneously or intrasplenically injected into nude mice (8 in each group), and the formation and growth of subcutane‑
ous xenografts a–c and liver metastatic tumors d and e were monitored. a The picture of subcutaneous xenografts. b Growth curves of subcutane‑
ous xenografts (*P < 0.05). c Average weight of subcutaneous xenografts. d Numbers of liver metastatic tumor nodules (*P < 0.05 compared with 
the vector group). e Gross tumor growth in the spleen and liver after intrasplenic injection of HCT116 cells stably transfected with ASB3 cDNA or its 
mutants (1 × 106 cells each) for 8 weeks. Left general spleen images; Right general liver images. f Representative images (upper) and hematoxylin 
and eosin (HE) staining pictures (lower) of the livers from each group; the metastatic tumor nodules are indicated with yellow arrows. The scale bars 
in HE staining pictures represent 100 µm
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clinical prognosis for CRC cases due to the shorter fol-
low-up. Second, further studies are required to confirm 
what molecules ASB3 directly interact with to play the 
tumor-suppressive role in CRC tumorigenesis.
Conclusions
There are frequent mutations (5.3%) and down-regulated 
expression (70.4%) of the ASB3 gene in Chinese patients 
with CRC. WT ASB3 inhibits CRC cell proliferation, 
Fig. 5 ASB3 inhibits the epithelial‑mesenchymal transition (EMT) of CRC cells. After THC8307 and SW620 cells were transiently transfected with 
siRNAs to knockdown ASB3 expression for 48 h, EMT markers were detected with Western blotting (a) and immunofluorescence assays (b), whereas 
EMT markers were detected with Western blotting (c) and immunofluorescence assays (d) in HCT116 or DLD‑1 cells stably transfected with ASB3 
cDNA or its mutants
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migration, and invasion in vitro and decreases the tumor-
igenicity and hepatic metastasis in vivo; whereas mutated 
ASB3 lost this tumor-suppressive role. In conclusion, 
dysfunctions of the ASB3 gene that result from mutations 
or down-regulated expression are possible events that 
lead to the pathogenesis or progression of CRC.
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